Erratum: efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care 2014;37:2149-2158

Diabetes Care. 2015 Mar;38(3):538. doi: 10.2337/dc15-er03.
No abstract available

Publication types

  • Published Erratum